Assembly Biosciences (NASDAQ:ASMB) Receives Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report released on Friday,Benzinga reports.

Separately, Jefferies Financial Group raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $2.00 to $35.00 in a research report on Friday, September 20th.

Assembly Biosciences Price Performance

Shares of NASDAQ ASMB opened at $15.16 on Friday. The company’s fifty day simple moving average is $16.05 and its 200 day simple moving average is $15.59. Assembly Biosciences has a 12-month low of $9.12 and a 12-month high of $19.93.

Insiders Place Their Bets

In other Assembly Biosciences news, major shareholder Alexander Schornstein acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, October 8th. The stock was bought at an average price of $14.58 per share, with a total value of $145,800.00. Following the completion of the acquisition, the insider now owns 703,113 shares of the company’s stock, valued at $10,251,387.54. This trade represents a 1.44 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 394 shares of company stock worth $5,894 in the last three months. 5.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in shares of Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 3,442 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 7,690 shares during the last quarter. FMR LLC grew its stake in shares of Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 3,635 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Assembly Biosciences by 39.2% in the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after acquiring an additional 15,451 shares during the period. Finally, Armistice Capital LLC bought a new stake in Assembly Biosciences in the second quarter valued at $6,421,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.